Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Application

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search

Search term:

Results 1 - 10 of 10
EC Number Application Commentary Reference
Show all pathways known for 1.14.14.32Display the word mapDisplay the reaction diagram Show all sequences 1.14.14.32drug development regioisomeric 17beta-N-phenylpyrazolyl steroid derivatives have weak inhibitory effect on 17alpha-hydroxylase/C17,20-lyase 706778
Show all pathways known for 1.14.14.32Display the word mapDisplay the reaction diagram Show all sequences 1.14.14.32drug development silencing CYP17 expression may be a strategy for therapy of hyperandrogenism diseases, and also sets an example for the use of RNAi technology in endocrine diseases 706689
Show all pathways known for 1.14.14.32Display the word mapDisplay the reaction diagram Show all sequences 1.14.14.32medicine combined 17alpha-hydroxyprogesterone aldolase/17,20-lyase deficiency is a rare, autosomal recessive form of congenital adrenal hyperplasia 690654
Show all pathways known for 1.14.14.32Display the word mapDisplay the reaction diagram Show all sequences 1.14.14.32medicine homology modelling of the enzyme cytochrome P450 17alpha-hydroxylase/17,20-lyase (P450c17)-a target for prostate cancer chemotherapy-from the crystal structure of P450BM-3 5131
Show all pathways known for 1.14.14.32Display the word mapDisplay the reaction diagram Show all sequences 1.14.14.32medicine inhibition of 17alpha-hydroxylase-C(17,20)-lyase can block androgen synthesis at an early stage, and may therefore be useful in the treatment of prostatic carcinoma 695147
Show all pathways known for 1.14.14.32Display the word mapDisplay the reaction diagram Show all sequences 1.14.14.32medicine inhibition of EC 4.1.2.30 is a potential therapeutic approach for the treatment of both breast and prostrate cancers 5130
Show all pathways known for 1.14.14.32Display the word mapDisplay the reaction diagram Show all sequences 1.14.14.32medicine inhibitor VT-464 displays selective suppression of androgen synthesis through CYP17 lyase inhibition. VT-464 shows a greater decrease in androgen receptor transactivation than inhibitor abiraterone 745754
Show all pathways known for 1.14.14.32Display the word mapDisplay the reaction diagram Show all sequences 1.14.14.32medicine inhibitors of 17alpha-hydroxylase/17,20 lyase are a class of anti-prostate cancer agents 694115
Show all pathways known for 1.14.14.32Display the word mapDisplay the reaction diagram Show all sequences 1.14.14.32medicine inhibitors of 17alpha-hydroxylase/17,20 lyase are a new class of anti-prostate cancer agents 694117
Show all pathways known for 1.14.14.32Display the word mapDisplay the reaction diagram Show all sequences 1.14.14.32medicine partial 17alpha-hydroxylase/17,20-lyase deficiency is a very rare form of congenital adrenal hyperplasia 693809
Results 1 - 10 of 10